Bausch + Lomb Corporation BLCO
Set alert
At close · Oct 30
After hours · Oct 30, 5:05 PM ET
- YTD
- +17.10%
- 1 year
- +32.10%
- Open
- 20.85
- Prev close
- 20.40
- Mkt cap
- 7.15B
- Vol
- 1.43M
- Avg vol
- 539.72K
- EPS
- -0.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.83
- High
- 20.85
- Forward P/E
- 16.72
- Beta
- 0.00
- Short ratio
- 5.12
- Inst. own
- 11.24%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 17, 2027
- 50-d avg
- 17.29
- 200-d avg
- 16.66
- 1y target
- 21.64
3M chart
Events in this range
- Sep 15, 2026Rating: Needham · Hold → Hold
- Oct 7, 2026Rating: Barclays · — → Overweight
- Oct 28, 2026Earnings: 0.34; estimate 0.2145; surprise 58.51%
- Oct 29, 2026Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Oct 29, 2026Rating: RBC Capital · Outperform → Outperform
- Oct 29, 2026Rating: Citigroup · Buy → Buy
- Oct 29, 2026Rating: JP Morgan · Neutral → Neutral
Signals (28)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 28, 2026 | 4 days ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 12, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 7, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| RSI: Overbought | Sep 2, 2026 | 2 months ago |
| MACD: Buy Signal | Sep 1, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
Key statistics
- Market cap
- 7.14B
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 16.72
- PEG ratio
- 0.89
- Price / sales
- 1.32
- Price / book
- 1.10
- EPS (TTM)
- -0.32
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -2.05%
- Revenue (TTM)
- 5.42B
- Revenue growth
- 7.30%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 357.50M
- Short % of float
- 5.55%
- 50-day average
- 17.29
- 200-day average
- 16.66
Analyst view
Consensus: buy
- Target (low)
- 18.00
- Target (mean)
- 21.64
- Target (high)
- 26.00
- Strong buy2
- Buy5
- Hold7
- Sell0
- Strong sell1
Next earnings
Feb 17, 2027
Expected Feb 17, 2027. Consensus EPS estimate 0.37246.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 17, 2027 | Dec 30, 2026 | 0.35 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 0.2145 | 0.34 | +0.13 | +58.51% |
| Jul 29, 2026 | Jun 30, 2026 | 0.1544 | 0.16 | +0.01 | +3.63% |
| Apr 29, 2026 | Mar 31, 2026 | 0.06 | 0.08 | +0.02 | +33.33% |
| Feb 18, 2026 | Dec 31, 2025 | 0.35 | 0.32 | -0.03 | -8.57% |
| Oct 29, 2025 | Sep 30, 2025 | 0.16 | 0.18 | +0.02 | +12.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | JP Morgan | main | Neutral | Neutral |
| Oct 29, 2026 | Citigroup | main | Buy | Buy |
| Oct 29, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 29, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 7, 2026 | Barclays | init | — | Overweight |
| Sep 15, 2026 | Needham | reit | Hold | Hold |
About Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- Canada
- Website
- bausch.com
News
- JP Morgan Maintains Neutral on Bausch & Lomb, Raises Price Target to $22
- RBC Capital Maintains Outperform on Bausch & Lomb, Raises Price Target to $23
- Wells Fargo Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $19
- Bausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient Education
- What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call
- Bausch + Lomb Corporation (BLCO) Q3 2026 Earnings Call Transcript
- Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates
- Bausch & Lomb Q3 Adj. EPS $0.34 Beats $0.22 Estimate, Sales $1.375B Beat $1.373B Estimate
- Bausch & Lomb Raises FY2026 Sales Guidance from $5.440B-$5.540B to $5.450B-$5.550B vs $5.496B Est
- Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance
Your note
Sign in to keep a note on BLCO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAILEY AMBROSE ROBERT DOUGLAS J.D. | Officer | Stock Award(Grant) | Aug 4, 2026 | 264,241 |
| BERNIER NATHALIE D | Director | Stock Award(Grant) | May 25, 2026 | 85,505 |
| BONNEFOY LUC | Officer | Stock Award(Grant) | Aug 4, 2026 | 103,801 |
| ELDESSOUKY OSAMA A | Chief Financial Officer | Stock Award(Grant) | Aug 4, 2026 | 393,527 |
| ELDESSOUKY SAM | Chief Financial Officer | Purchase | Mar 5, 2026 | 407,130 |
| HASHAD YEHIA | Officer | Stock Award(Grant) | Aug 4, 2026 | 187,350 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Icahn Carl C | 0.98% | 3,500,000 | 69.86M | Jun 29, 2026 |
| Deutsche Bank AG | 0.96% | 3,423,046 | 68.32M | Jun 29, 2026 |
| Oaktree Capital Management LP | 0.96% | 3,441,042 | 68.68M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 0.93% | 3,323,021 | 66.33M | Jun 29, 2026 |
| Davidson Kempner Capital Management LP | 0.88% | 3,158,972 | 63.05M | Jun 29, 2026 |
| Goldentree Asset Management LP | 0.74% | 2,660,508 | 53.10M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price High Yield Fund, Inc. | 0.23% | 837,050 | 16.71M | Aug 30, 2026 |
| TR PRICE-Price (T.Rowe) U.S. High Yield Trust | 0.13% | 454,220 | 9.07M | Jun 29, 2026 |
| T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Dynamic Credit Fd. | 0.06% | 204,491 | 4.08M | Jun 29, 2026 |
| T. ROWE PRICE Inst. INCOME Fd.S, INC.-T. Rowe Price Inst. High Yield F | 0.06% | 218,211 | 4.36M | Aug 30, 2026 |
| Unified Series Trust-BALLAST SMALL/MID CAP ETF | 0.04% | 147,837 | 2.95M | Jun 29, 2026 |
| Gabelli Healthcare & WellnessRx Trust | 0.04% | 144,000 | 2.87M | Sep 29, 2026 |